prikaz prve stranice dokumenta Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
  Preuzmi
PDF 913.81 KB
Znanstveni rad - Izvorni znanstveni rad
Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
Croatian Medical Journal, 63 (2022), 6; 536-543. https://doi.org/10.3325/cmj.2022.63.536
Lucijanić, Marko; Bušić, Nikolina; Bistrović, Petra; Papić, Ivan; Zelenika Margeta, Marina; Babić, Paško; Barčan, Mihaela; Pasarić, Antica; Mustapić, Mirna; Piskač Živković, Nevenka; Ortner Hadžiabdić, Maja; Lucijanić, Tomo; Lukšić, Ivica; Baršić, Bruno

Citirajte ovaj rad

Lucijanić, M., Bušić, N., Bistrović, P., Papić, I., Zelenika Margeta, M., Babić, P. ... Baršić, B. (2022). Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry. Croatian Medical Journal, 63. (6), 536-543. doi: 10.3325/cmj.2022.63.536

Lucijanić, Marko, et al. "Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry." Croatian Medical Journal, vol. 63, br. 6, 2022, str. 536-543. https://doi.org/10.3325/cmj.2022.63.536

Lucijanić, Marko, Nikolina Bušić, Petra Bistrović, Ivan Papić, Marina Zelenika Margeta, Paško Babić, Mihaela Barčan, et al. "Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry." Croatian Medical Journal 63, br. 6 (2022): 536-543. https://doi.org/10.3325/cmj.2022.63.536

Lucijanić, M., et al. (2022) 'Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry', Croatian Medical Journal, 63(6), str. 536-543. doi: 10.3325/cmj.2022.63.536

Lucijanić M, Bušić N, Bistrović P, Papić I, Zelenika Margeta M, Babić P, i sur.. Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry. Croatian Medical Journal [Internet]. 31.12.2022. [pristupljeno 20.12.2024.];63(6):536-543. doi: 10.3325/cmj.2022.63.536

M. Lucijanić, et al., "Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry", Croatian Medical Journal, vol. 63, br. 6, str. 536-543, Prosinac 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:523196. [Citirano: 20.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:523196
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Real-life experience with remdesivir for treatment of hospitalized coronavirus disease 2019 patients: matched case-control study from a large tertiary hospital registry
AutorMarko Lucijanić
AutorNikolina Bušić
AutorPetra Bistrović
AutorIvan Papić
AutorMarina Zelenika Margeta
AutorPaško Babić
AutorMihaela Barčan
AutorAntica Pasarić
AutorMirna Mustapić
AutorNevenka Piskač Živković
AutorMaja Ortner Hadžiabdić
AutorTomo Lucijanić
AutorIvica Lukšić
AutorBruno Baršić
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA MAKSILOFACIJALNU KIRURGIJU SA STOMATOLOGIJOM)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Kirurgija
Sažetak (engleski)
Aim: To evaluate the association of remdesivir use and the survival of hospitalized patients with coronavirus disease 2019 (COVID-19). ----- Methods: We retrospectively reviewed the medical records of 5959 COVID-19 patients admitted to our tertiary-level hospital from March 2020 to June 2021. A total of 876 remdesivir-treated patients were matched with 876 control patients in terms of age, sex, Charlson comorbidity index (CCI), WHO-defined COVID-19 severity on admission, and oxygen requirement at the time of remdesivir use. ----- Results: Among 1752 COVID-19 patients (median age 66 years, 61.8% men), 1405 (80.2%) had severe and 311 (17.8%) had critically severe COVID-19 on admission. Remdesivir was given at a median of one day after hospital admission and at a median of eight days from the onset of symptoms. Overall, 645 (73.6%) patients received remdesivir before high-flow oxygen therapy (HFOT) or mechanical ventilation (MV), 198 (22.6%) after HFOT institution, and 83 (9.5%) after MV institution. Remdesivir use was associated with improved survival in the entire cohort (hazard ratio 0.79, P=0.006). Survival benefit was evident among patients receiving remdesivir during low-flow oxygen requirement (hazard ratio 0.61, P<0.001) but not among patients who received it after starting HFOT (P=0.499) or MV (P=0.380). ----- Conclusion: Remdesivir, if given during low-flow oxygen therapy, might be associated with survival benefit in hospitalized COVID-19 patients.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaCroatian Medical Journal
Brojčani podacivol. 63, br. 6, str. 536-543
p-ISSN0353-9504
e-ISSN1332-8166
DOIhttps://doi.org/10.3325/cmj.2022.63.536
URN:NBNurn:nbn:hr:105:523196
Datum objave publikacije2022-12-31
URL dokumentahttp://www.cmj.hr/2022/63/6/36597565.htm
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2023-01-16 12:48:19